Doing some research on $ABSI. I like the drug discovery space but have to be patient for things to play out. I still have challenges in valuing these drug discovery companies. It is easier for me to value the Gene Editing companies.

Sean McClain, CEO of $ABSI, provided some interesting value value statements:

1) With the AI models they are able to identify drug candidates in 14 months versus the traditional 24-36 month range.
2) Will be in the clinic in 24 months, normally takes 5.5 years to get into the clinic.
3) Invested $13-$15 million to get the asset into the clinic. Traditionally it costs between $50 - $100 million.

They are able to change the paradigm and economics of how a traditional biotech has worked. Working on their own pipeline and partnered programs (similar to $RXRX, $SDGR, $DNA, $ABCL). While they will get more shots on goal, it will be important for them to have higher success rate compared to the traditional drug discovery process where 90% fail.

I wonder whether any of the Gene Editing are leveraging AI to target hard to address targets, e.g., CAR-T companies targeting solid tumors.
#ABSI #ABSI